Literature DB >> 25583490

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.

Adam G Walker1, Cody J Wenthur1, Zixiu Xiang1, Jerri M Rook1, Kyle A Emmitte2, Colleen M Niswender1, Craig W Lindsley2, P Jeffrey Conn3.   

Abstract

Clinical studies have revealed that genetic variations in metabotropic glutamate receptor 3 (mGlu3) affect performance on cognitive tasks dependent upon the prefrontal cortex (PFC) and may be linked to psychiatric conditions such as schizophrenia, bipolar disorder, and addiction. We have performed a series of studies aimed at understanding how mGlu3 influences PFC function and cognitive behaviors. In the present study, we found that activation of mGlu3 can induce long-term depression in the mouse medial PFC (mPFC) in vitro. Furthermore, in vivo administration of a selective mGlu3 negative allosteric modulator impaired learning in the mPFC-dependent fear extinction task. The results of these studies implicate mGlu3 as a major regulator of PFC function and cognition. Additionally, potentiators of mGlu3 may be useful in alleviating prefrontal impairments associated with several CNS disorders.

Entities:  

Keywords:  GRM3; fear extinction; group II mGlu receptors; long-term depression; medial prefrontal cortex

Mesh:

Substances:

Year:  2015        PMID: 25583490      PMCID: PMC4313856          DOI: 10.1073/pnas.1416196112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  Neural circuits underlying the pathophysiology of mood disorders.

Authors:  Joseph L Price; Wayne C Drevets
Journal:  Trends Cogn Sci       Date:  2011-12-21       Impact factor: 20.229

2.  Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala.

Authors:  Sarah J Lucas; Zuner A Bortolotto; Graham L Collingridge; David Lodge
Journal:  Neuropharmacology       Date:  2012-04-17       Impact factor: 5.250

Review 3.  Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).

Authors:  Sylvain Celanire; Iyassu Sebhat; Juergen Wichmann; Stanislas Mayer; Stephan Schann; Silvia Gatti
Journal:  Expert Opin Ther Pat       Date:  2014-12-01       Impact factor: 6.674

4.  mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests.

Authors:  Mira Lainiola; Chiara Procaccini; Anni-Maija Linden
Journal:  Behav Brain Res       Date:  2014-03-11       Impact factor: 3.332

Review 5.  Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions.

Authors:  David A Lewis
Journal:  Eur J Neurosci       Date:  2012-06       Impact factor: 3.386

Review 6.  Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.

Authors:  P Jeffrey Conn; Craig W Lindsley; Jens Meiler; Colleen M Niswender
Journal:  Nat Rev Drug Discov       Date:  2014-09       Impact factor: 84.694

7.  Gating of fear in prelimbic cortex by hippocampal and amygdala inputs.

Authors:  Francisco Sotres-Bayon; Demetrio Sierra-Mercado; Enmanuelle Pardilla-Delgado; Gregory J Quirk
Journal:  Neuron       Date:  2012-11-21       Impact factor: 17.173

8.  Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Authors:  Aubin Michalon; Michael Sidorov; Theresa M Ballard; Laurence Ozmen; Will Spooren; Joseph G Wettstein; Georg Jaeschke; Mark F Bear; Lothar Lindemann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

9.  Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes.

Authors:  Ryuta Fujioka; Takenobu Nii; Akiko Iwaki; Atsushi Shibata; Isao Ito; Kiyoyuki Kitaichi; Masatoshi Nomura; Satoko Hattori; Keizo Takao; Tsuyoshi Miyakawa; Yasuyuki Fukumaki
Journal:  Mol Brain       Date:  2014-04-23       Impact factor: 4.041

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  48 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum.

Authors:  Kari A Johnson; Yolanda Mateo; David M Lovinger
Journal:  Neuropharmacology       Date:  2017-01-31       Impact factor: 5.250

3.  Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Authors:  Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-06-08       Impact factor: 4.418

4.  Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.

Authors:  Juliet McColm; Claire Brittain; Subha Suriyapperuma; Steven Swanson; Sitra Tauscher-Wisniewski; Joanne Foster; Danny Soon; Kimberley Jackson
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

Review 5.  A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.

Authors:  Joseph H Neale; Rafal Olszewski
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

6.  Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation.

Authors:  Adam G Walker; Douglas J Sheffler; Andrew S Lewis; Jonathan W Dickerson; Daniel J Foster; Rebecca K Senter; Mark S Moehle; Xiaohui Lv; Branden J Stansley; Zixiu Xiang; Jerri M Rook; Kyle A Emmitte; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2017-06-30       Impact factor: 7.853

Review 7.  Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Authors:  Daniel J Foster; P Jeffrey Conn
Journal:  Neuron       Date:  2017-05-03       Impact factor: 17.173

8.  Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.

Authors:  Julie L Engers; Katrina A Bollinger; Rebecca L Weiner; Alice L Rodriguez; Madeline F Long; Megan M Breiner; Sichen Chang; Sean R Bollinger; Michael Bubser; Carrie K Jones; Ryan D Morrison; Thomas M Bridges; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2017-08-15       Impact factor: 4.345

9.  Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Authors:  Katrina A Bollinger; Andrew S Felts; Christopher J Brassard; Julie L Engers; Alice L Rodriguez; Rebecca L Weiner; Hyekyung P Cho; Sichen Chang; Michael Bubser; Carrie K Jones; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2017-08-03       Impact factor: 4.345

10.  Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex.

Authors:  Takaki Kiritoshi; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2015-04-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.